Brief: Karolinska Development Gets Update From Organon Concerning OG-6219
03/07/2025 06:02
July 3 (Reuters) - Karolinska Development AB KDEV.ST: REG-KAROLINSKA DEVELOPMENT RECEIVES UPDATE FROM ORGANON CONCERNING OG-6219 ORGANON PLANS TO DISCONTINUE CLINICAL DEVELOPMENT OF DRUG CANDIDATE DRUG CANDIDATE OG-6219 FAILED TO DEMONSTRATE IMPROVEMENT IN MODERATE-TO-SEVERE ENDOMETRIOSIS-RELATED OVERALL PELVIC PAIN RECOGNIZES NEED TO IMPLEMENT AN IMPAIRMENT IF ORGANON DECIDES TO DISCONTINUE PROJECT Source text: ID:nGNE9xgHTj Further company coverage: KDEV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue